Skip to Content

Zarxio Approval History

FDA Approved: Yes (First approved March 6, 2015)
Brand name: Zarxio
Generic name: filgrastim-sndz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Neutropenia Associated with Chemotherapy

Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.

Development History and FDA Approval Process for Zarxio

DateArticle
Mar  6, 2015Approval FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz)
Jan  7, 2015Sandoz Biosimilar Filgrastim Recommended for Approval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide